Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6results about How to "Reduce cell viability" patented technology

MMP2 gene promoter region SNP (Single Nucleotide Polymorphism) site and application thereof in pig breeding

ActiveCN119410782Areduce cell viabilityInhibition of ferroptosisMicrobiological testing/measurementFood processingBiotechnologyGranular cell
The invention discloses an MMP2 gene promoter region SNP (Single Nucleotide Polymorphism) site and application thereof in pig breeding. According to the invention, an MMP2 gene promoter region is taken as a research object, and the relevance between the MMP2 gene promoter region and sow sexual maturity is researched by adopting a molecular and cell biology method, so that the situation that g.30088284G > A site and g.30088004C > T site are obviously related to the group maturity day age of Dumet black pigs is found; then different vectors are transfected, and different influences of different genotypes of the sites on the activity of the IRS1 gene promoter are studied. Further, sow ovarian granular cells are used as experimental materials, experimental technologies such as transcriptome sequencing, a total iron colorimetric method and a malondialdehyde colorimetric method are adopted, the influence of the MMP2 gene on the transcriptome level and ferroptosis of the sow ovarian granular cells is researched, and it is found that cell transcriptome differential genes influenced by the MMP2 gene are mainly enriched to signal channels such as cell differentiation; and ferroptosis of cells is promoted.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Pharmaceutical composition for inhibiting tumor drug resistance and application thereof

The invention discloses a pharmaceutical composition for inhibiting tumor drug resistance and application thereof. The pharmaceutical composition comprises an exosome inhibitor, nintedanib and gemcitabine, the exosome inhibitor, the nintedanib and the gemcitabine are used in a combined manner, so that the cell viability of the CTS can be remarkably reduced, and the proportion of apoptotic cells in the CTS can be remarkably increased; the pharmaceutical composition interferes with the mutual transformation process between normal fibroblasts and CAFs, and inhibits secretion and release of EVs and reduces formation of new CAFs while restoring the CAFs existing in TME to normal fibroblasts, thereby successfully reversing the drug resistance of tumors.
Owner:浙江迈镝生物科技有限公司

Application of streptococcus sanguis extract in preparation of medicines for preventing and treating cancers

ActiveCN119139359Areduce cell viabilityprevent invasionAntinoxious agentsUnknown materialsPhosphorylationStreptococcus sanguinis
The invention relates to application of streptococcus sanguis extract in preparation of drugs for preventing and treating cancers, and belongs to the technical field of medicines. In order to develop the new application of the streptococcus sanguis extract XLS in cancer treatment, the invention provides the application of the streptococcus sanguis extract in preparation of drugs for preventing and treating cancers. The invention demonstrates the inhibition effect of the streptococcus sanguis extract XLS on an ovarian cancer cell line SKOV3. CCK-8 experiments prove that the streptococcus sanguis extract XLS can reduce the cell activity of SKOV3 and has an inhibiting effect on cell proliferation, invasion and migration of the SKOV3. Molecular biology experiment research shows that XLS inhibits activation of a PI3K / AKT signal channel by inhibiting phosphorylation of AKT, regulates expression of apoptosis-related genes and induces SKOV3 cell apoptosis. In addition, XLS further damages the structure and function of tumor cells by means of destroying mitochondrial membrane potential, increasing oxidative stress, Ca < 2 + > imbalance and the like.
Owner:HEI LONG JIANG SHENG YI YUAN (HEI LONG JIANG SHENG ZHONG RI YOU YI YI YUAN HEI LONG JIANG SHENG SHENG ZHI BAO JIAN FU WU ZHONG XIN HEI LONG JIANG SHENG PI FU XING BING FANG ZHI ZHONG XIN)

Application of LFA-1 neutralizing antibody in medicine for relieving neuroinflammation of Parkinson's disease

PendingCN119280395Areduce releasereduce cell viabilityNervous disorderAntibody ingredientsIn vitro stimulationAntiendomysial antibodies
The invention discloses an application of an anti-lymphocyte function associated antigen 1 (LFA-1) neutralizing antibody in a medicine for relieving neuroinflammation of Parkinson's disease, and belongs to the technical field of biological medicines. The invention further discloses a preparation method of the anti-lymphocyte function associated antigen 1 (LFA-1) neutralizing antibody and an application of the anti-lymphocyte function associated antigen 1 (LFA-1) neutralizing antibody in the medicine for relieving the neuroinflammation of the Parkinson's disease. The method comprises the following steps: co-culturing Teff cells stimulated and activated in vitro or Teff cells activated after being treated by using an LFA-1 neutralizing antibody with MN9D cells of an MPP + untreated group and an MPP + treated group for 48 hours, and observing the influence of the Teff cells on the activity of the MN9D cells, the number of apoptotic and necrotic cells, LDH release and apoptotic protein expression conditions. Results show that after pretreatment with the LFA-1 neutralizing antibody, MN9D cell viability decline, apoptosis and necrotic cell number increase, LDH release increase and apoptosis protein expression up-regulation caused by Teff cells are all relieved (Plt; 0.05) of the method.
Owner:NANTONG UNIV

Application of Anluo chemical fiber pill in preparation of medicine for inhibiting liver cancer cell proliferation and promoting liver cancer cell apoptosis

The invention belongs to the technical field of traditional Chinese medicines, particularly discloses application of an Anluo chemical fiber pill in preparation of medicines for inhibiting liver cancer cell proliferation and promoting liver cancer cell apoptosis, and discloses that the Anluo chemical fiber pill can reduce the cell survival rate of human liver cancer cells Hep G2, Hep 3B and SK-Hep-1 and has time and dose dependence; the Anluo chemical fiber pills can inhibit proliferation, invasion and migration of Hep G2 and Hep 3B cells and induce apoptosis of the Hep G2 and Hep 3B cells at the same time, and the apoptosis mostly occurs at the early stage of cell apoptosis; the Anluo chemical fiber pill can promote apoptosis of Hep G2 and Hep 3B cells by increasing the content of ROS in the Hep G2 and Hep 3B cells, and has dependence on time and dosage, so that the Anluo chemical fiber pill can be used for preparing the medicine for inhibiting liver cancer cell proliferation and promoting apoptosis of liver cancer cells.
Owner:TONGHUA NORMAL UNIV

Use of polysaccharide coating film in the preparation of cell culture products

PendingCN122235064Abeneficial differentiationreduce sheddingSkeletal/connective tissue cells
This invention discloses the application of a polysaccharide coating membrane in the preparation of cell culture products, belonging to the field of cell culture food technology. Specifically, after cells are seeded onto a scaffold, a polysaccharide coating membrane is formed around it. This can alleviate the phenomenon of cells detaching from the scaffold during culture, thereby ensuring the effective proliferation and differentiation of muscle stem cells and / or adipose stem cells on the scaffold, providing a new solution for the efficient and standardized production of cell culture products.
Owner:NANJING JOES FUTURE FOOD TECH CO LTD